Nazy Zomorodian

Title(s)Assistant Adjunct Professor, Urology
SchoolMedicine
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Talazoparib Plus Enzalutamide in Patients With HRR-Deficient mCRPC: Practical Implementation Steps for Oncology Nurses and Advanced Practice Providers. Clin J Oncol Nurs. 2024 Sep 17; 28(5):483-491. Lloyd J, Zomorodian N, Devgan G, Batten J. PMID: 39324718.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    2. A Phase I, Open-label, Dose-escalation, and Cohort Expansion Study to Evaluate the Safety and Immune Response to Autologous Dendritic Cells Transduced With AdGMCA9 (DC-AdGMCAIX) in Patients With Metastatic Renal Cell Carcinoma. J Immunother. 2020 Nov/Dec; 43(9):273-282. Faiena I, Comin-Anduix B, Berent-Maoz B, Bot A, Zomorodian N, Sachdeva A, Said J, Cheung-Lau G, Pang J, Macabali M, Chodon T, Wang X, Cabrera P, Kaplan-Lefko P, Chamie K, Belldegrun AS, Pantuck AJ, Drakaki A. PMID: 32925563.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCellsCTClinical Trials
    3. The intraprostatic immune environment after stereotactic body radiotherapy is dominated by myeloid cells. Prostate Cancer Prostatic Dis. 2021 03; 24(1):135-139. Nickols NG, Ganapathy E, Nguyen C, Kane N, Lin L, Diaz-Perez S, Nazarian R, Mathis C, Felix C, Basehart V, Zomorodian N, Kwak J, Kishan AU, King CR, Kupelian PA, Rettig MB, Steinberg ML, Cao M, Knudsen BS, Chu FI, Romero T, Elashoff D, Reiter RE, Schaue D. PMID: 32647353; PMCID: PMC7794088.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCellsCTClinical Trials
    4. Phase 1 Trial of Stereotactic Body Radiation Therapy Neoadjuvant to Radical Prostatectomy for Patients With High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2020 11 15; 108(4):930-935. Parikh NR, Kishan AU, Kane N, Diaz-Perez S, Ganapathy E, Nazarian R, Felix C, Mathis C, Bradley M, Sachdeva A, Wyatt B, Basehart V, Zomorodian N, Lin L, King CR, Kupelian PA, Rettig MB, Steinberg ML, Cao M, Knudsen BS, Elashoff D, Schaue D, Reiter RE, Nickols NG. PMID: 32562839; PMCID: PMC8261839.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    5. Salvage-targeted kidney cancer therapy in patients progressing on high-dose interleukin-2 immunotherapy: the UCLA experience. Cancer J. 2013 May-Jun; 19(3):189-96. Birkhäuser FD, Pantuck AJ, Rampersaud EN, Wang X, Kroeger N, Pouliot F, Zomorodian N, Riss J, Li G, Kabbinavar FF, Belldegrun AS. PMID: 23708063.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    6. Clinical, molecular, and genetic correlates of lymphatic spread in clear cell renal cell carcinoma. Eur Urol. 2012 May; 61(5):888-95. Kroeger N, Seligson DB, Klatte T, Rampersaud EN, Birkhäuser FD, Rao PN, Leppert JT, Zomorodian N, Kabbinavar FF, Belldegrun AS, Pantuck AJ. PMID: 22269604.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    7. Prognostic value of microvascular invasion in predicting the cancer specific survival and risk of metastatic disease in renal cell carcinoma: a multicenter investigation. J Urol. 2012 Feb; 187(2):418-23. Kroeger N, Rampersaud EN, Patard JJ, Klatte T, Birkhäuser FD, Shariat SF, Lang H, Rioux-Leclerq N, Remzi M, Zomorodian N, Kabbinavar FF, Belldegrun AS, Pantuck AJ. PMID: 22177164.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    8. Smoking negatively impacts renal cell carcinoma overall and cancer-specific survival. Cancer. 2012 Apr 01; 118(7):1795-802. Kroeger N, Klatte T, Birkhäuser FD, Rampersaud EN, Seligson DB, Zomorodian N, Kabbinavar FF, Belldegrun AS, Pantuck AJ. PMID: 21997347.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    9. Pathological, immunohistochemical and cytogenetic features of papillary renal cell carcinoma with clear cell features. J Urol. 2011 Jan; 185(1):30-5. Klatte T, Said JW, Seligson DB, Rao PN, de Martino M, Shuch B, Zomorodian N, Kabbinavar FF, Belldegrun AS, Pantuck AJ. PMID: 21074210.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    10. Chromosome 9p deletions identify an aggressive phenotype of clear cell renal cell carcinoma. Cancer. 2010 Oct 15; 116(20):4696-702. La Rochelle J, Klatte T, Dastane A, Rao N, Seligson D, Said J, Shuch B, Zomorodian N, Kabbinavar F, Belldegrun A, Pantuck AJ. PMID: 20629029.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCells
    11. Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. Cancer Epidemiol Biomarkers Prev. 2009 Mar; 18(3):894-900. Klatte T, Seligson DB, LaRochelle J, Shuch B, Said JW, Riggs SB, Zomorodian N, Kabbinavar FF, Pantuck AJ, Belldegrun AS. PMID: 19240241.
      View in: PubMed   Mentions: 63     Fields:    Translation:Humans
    12. Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J Clin Oncol. 2009 Feb 10; 27(5):746-53. Klatte T, Rao PN, de Martino M, LaRochelle J, Shuch B, Zomorodian N, Said J, Kabbinavar FF, Belldegrun AS, Pantuck AJ. PMID: 19124809.
      View in: PubMed   Mentions: 84     Fields:    Translation:HumansCells
    13. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies. Cancer. 2008 Nov 01; 113(9):2457-63. Belldegrun AS, Klatte T, Shuch B, LaRochelle JC, Miller DC, Said JW, Riggs SB, Zomorodian N, Kabbinavar FF, Dekernion JB, Pantuck AJ. PMID: 18823034.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    14. The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma. J Urol. 2008 Jan; 179(1):61-6. Klatte T, Seligson DB, Leppert JT, Riggs SB, Yu H, Zomorodian N, Kabbinavar FF, Strieter RM, Belldegrun AS, Pantuck AJ. PMID: 17997430.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    15. A novel resectoscope for transurethral resection of bladder tumors and the prostate. J Urol. 2007 Dec; 178(6):2331-6; discussion 2336. Pantuck AJ, Baniel J, Kirkali Z, Klatte T, Zomorodian N, Yossepowitch O, Belldegrun AS. PMID: 17936809.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    16. Prognostic factors for renal cell carcinoma with tumor thrombus extension. J Urol. 2007 Oct; 178(4 Pt 1):1189-95; discussion 1195. Klatte T, Pantuck AJ, Riggs SB, Kleid MD, Shuch B, Zomorodian N, Kabbinavar FF, Belldegrun AS. PMID: 17698087.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCells
    17. Phase I, open-label, single-center, multiple-dose, dose-escalation clinical study of SUO11248 (sunitinib) in subjects with high-risk prostate cancer who have elected to undergo radical prostatectomy. Curr Urol Rep. 2007 Jan; 8(1):3-4. Pantuck AJ, Zomorodian N, Belldegrun AS. PMID: 17239310.
      View in: PubMed   Mentions: 4     Fields:    
    18. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res. 2006 Jul 01; 12(13):4018-26. Pantuck AJ, Leppert JT, Zomorodian N, Aronson W, Hong J, Barnard RJ, Seeram N, Liker H, Wang H, Elashoff R, Heber D, Aviram M, Ignarro L, Belldegrun A. PMID: 16818701.
      View in: PubMed   Mentions: 110     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    19. Phase-II Study of pomegranate juice for men with prostate cancer and increasing PSA. Curr Urol Rep. 2006 Jan; 7(1):7. Pantuck AJ, Zomorodian N, Belldegrun AS. PMID: 16480662.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimals
    20. Monoclonal antibody (MAB) in patients with advanced cancer. Curr Urol Rep. 2003 Feb; 4(1):11-2. Kim HL, Pantuck AJ, Zomorodian N, Belldegrun AS. PMID: 12537933.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    Nazy's Networks
    Concepts (121)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (13)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-6-g69de2244 on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California